
Over 75 drugs in development for Duchenne muscular dystrophy signal strong innovation in treatment options.
DelveInsight's 2026 report reveals a robust pipeline with 75+ drugs under development for Duchenne muscular dystrophy (DMD), involving 70+ companies. Key therapies focus on gene and mutation-targeted approaches to slow disease progression, addressing...


